Hosam K. Kamel, MD
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
Kamel H.; Testosterone and Resistance Training in AIDS. Ann Intern Med. 2001;135:64-65. doi: 10.7326/0003-4819-135-1-200107030-00027
Download citation file:
Published: Ann Intern Med. 2001;135(1):64-65.
TO THE EDITOR:
There are two points of interest in the article by Grinspoon and colleagues (1), which examined the effects of testosterone supplementation on muscle mass and strength in patients with AIDS cachexia. First, all patients had normal free testosterone levels (that is, they were eugonadal). Second, the dosage of testosterone enanthate used (200 mg/wk) was twice the physiologic replacement dosage.
Eight published randomized, controlled trials have examined testosterone supplementation in men at doses that produced physiologic serum concentrations and assessed the effects of such supplementation on muscle mass and strength. Results from these trials suggest that testosterone supplementation at these doses increased muscle mass and strength in hypogonadal but not eugonadal patients. Testosterone doses that produced supraphysiologic concentrations of testosterone in eugonadal patients had inconsistent effects on muscle. Earlier studies had several shortcomings and produced inconclusive results (2, 3). In 1996, Bhasin and coworkers (4), in a well-designed study, reported that a supraphysiologic dosage of testosterone enanthate (600 mg/wk for 10 weeks) increased muscle size and strength in a group of eugonadal normal men. The study by Grinspoon and colleagues reports similar findings in a group of eugonadal men with AIDS wasting. The short-term administration of these supraphysiologic dosages of testosterone did not cause adverse events in either study sample.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only